App-Quantinova.ai

Relationship between rising bilateral mastectomy rates and increased use of neoadjuvant chemotherapy (NAC) in California, 1998-2012.

Irene Wapnir - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Impact of breast magnetic resonance imaging (MRI) on long-term outcome after breast conservation therapy (BCT).

Carolyn J. Kushner - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Locoregional treatment (LRT) and overall survival (OS) of men with T1a,b,cN0M0 breast cancer: a population-based study.

Jose Pablo Leone - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Association of higher health care costs with contralateral prophylactic mastectomy (CPM) within two years of initial surgery attributable to breast reconstruction.

Mary Chen Schroeder - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

N/A

Survival outcomes after adjuvant radiation in women 65 years diagnosed with ductal carcinoma in-situ: Analysis of National Cancer Data Base.

Wenli Gao - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Optimal patient selection for electron intraoperative radiotherapy (IORT) as sole treatment for breast cancer.

Kathleen C. Horst - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Nipple skin-sparing mastectomy: 15 year experience of expanding indications.

Amy Elizabeth Rivere - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

N/A

Trends in mastectomy rates over time in elderly women with stage I, hormone-sensitive breast cancer: A SEER-based study.

Jose G. Bazan - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Rate of sentinel lymph node biopsy in patients undergoing mastectomy for ductal carcinoma in situ with and without micro-invasion.

Patience Odele - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Correlation between progression free survival and overall survival in patients with metastatic breast cancer receiving anthracyclines, taxanes or targeted therapies: A trial level meta-analysis.

Georges Adunlin - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

taxane

New threshold of ER positivity in early stage HER2- breast cancer.

Takeo Fujii - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

A measure of intratumor heterogeneity to predict metastasis and metastasis-free survival in patients with triple-negative breast cancer.

Yucai Wang - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Triple-negative breast cancer

N/A

Analysis of BRCA1-related functional associations in sporadic triple negative breast cancer: A network-based approach.

Arcangela De Nicolo - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Triple-negative breast cancer

N/A

Androgen receptor (AR) expression in primary breast cancer (BC): Correlations with clinical characteristics and outcomes.

Neelima Vidula - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Androgen Tear

The association of age with breast cancer mortality within four race/ethnicities for the triple negative and HER2-overexpressing subtypes.

Carol Parise - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Cobimetinib (C) + paclitaxel (P) as first-line treatment in patients (pts) with advanced triple-negative breast cancer (TNBC): Updated results and biomarker data from the phase 2 COLET study.

Adam Brufsky - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Triple-negative breast cancer

Cobimetinib

Recurrence and survival outcomes of triple-negative breast cancer survivors disease-free at 5-years and relationship to low hormone receptor positivity (1-9% versus <1%).

Sangeetha Meda Reddy - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Triple-negative breast cancer

N/A

RespondR signature to predict potential alternative therapies for taxane resistant triple-negative breast cancer patients.

Steven Allen Buechler - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Triple-negative breast cancer

Cisplatin

RespondR signature to predict response in TNBC patients treated with adjuvant taxane based chemotherapy in TCGA dataset.

Steven Allen Buechler - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

taxane

A novel single domain antibody (sdAb) SBT-100 to target intracellular STAT3 to affect growth and regression of human triple negative breast cancer (TNBC) cells.

Sunanda Singh - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Triple-negative breast cancer

N/A

Filters

255783 Abstracts